Search Results

Search Results
Search this site
90 results found with an empty search
Main Pages (28)
- Most Favored Nation | Partnership to Fight Chronic Disease
Policymakers continue to explore “Most Favored Nation” policies in a stated attempt to lower the cost of medicines. Unfortunately, these efforts do nothing to actually reduce costs for the millions of patients who rely on medicines to manage chronic diseases. Most Favored Nation RESOURCES > MOST FAVORED NATION Most Favored Nation Policymakers continue to explore “Most Favored Nation” policies in a stated attempt to lower the cost of medicines. Unfortunately, these efforts do nothing to actually reduce costs for the millions of patients who rely on medicines to manage chronic diseases. Broader consideration of the consequences of these types of policies on patient access and innovation, as well as a more realistic focus on the real drivers of cost in the system, such as insurance practices and pharmacy benefit managers, must remain a priority. Case Study: Rare Disease Under MFN U.S. Patients with Rare Diseases Benefit from Earlier Access to Treatment Compared to Years of Delay Faced by U.K. Patients Fact Sheet: Learning from Mistakes Learning from Europe's Mistakes: Why Most Favored Nation Pricing Threatens American Patients Case Study: Cancer Treatment Delays New Case Study Highlights the Risk of Severe Treatment Delays for U.S. Patients Fighting Cancer Due to MFN GLOBE/GUARD: "What They Are Saying" Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the proposed GLOBE and GUARD prescription drug pricing models on patient access in America. Analysis: Patients Paid the Price New Analysis: Patients Paid the Price When Europe Controlled Drug Costs The QALY Paradox: An Unintended Consequence Of Most Favored Nation Drug Pricing By Dominique Seo, Kenneth E. Thorpe, T. Joseph Mattingly II February 18, 2026 MFN: "What They Are Saying" Leading voices from patient, provider, and other stakeholder communities are raising serious concerns about the impact of the “Most Favored Nation” pricing proposal on patient access in America. PBM Reform, Not MFN Why PBM Reform, not MFN, is a Viable Path to Affordable Drug Access A Tale of Two Patients Same diagnosis. Different countries. Very different outcomes. Two people — one in the U.S., one in England — have the same symptoms at the same time, but disparities in drug access affect how quickly they get diagnosed and what treatment options are available. Explore how different two people's outcomes and quality of life can be just because of where they live. Paula & Pippa HER2-positive breast cancer Sam & Simon Small cell lung cancer (SCLC) Chronic Choices, Critical Voices YouTube Series To shed some light on concerns about the Most Favored Nation proposal and its impact on people living with chronic conditions, the Partnership to Fight Chronic Disease (PFCD) is hosting short discussions with health and policy experts to address challenges to patient access, discriminatory value metrics like the QALY, and threats to future innovation. PFCD's Ken Thorpe sits down with Daneen Sekoni , Vice President of Policy and Advocacy at Cancer Support Community , to discuss what proposed Most Favored Nation (MFN) drug pricing policies could mean for people living with cancer. They explore the importance of timely access to innovative cancer treatments, the potential impact of importing foreign pricing policies, implications for health equity, and how policymakers can address affordability without jeopardizing access to the next generation of breakthrough therapies. PFCD's Vice President of Policy Candace DeMatteis speaks with former Congressman and physician Dr. Michael C. Burgess about the real-world impact of government drug pricing mandates, formulary restrictions, foreign pricing models, QALYs, physician autonomy, and the future of patient-centered care for people managing chronic and rare diseases. PFCD's Vice President of Policy Candace DeMatteis and Alliance for Aging Research's Director of Public Policy and Government Relations Adina Lasser examine the “Most Favored Nation” drug pricing proposal and what it could mean for older Americans who rely on Medicare. They discuss the flaws of the quality-adjusted life year (QALY) and explore better policy solutions to lower drug costs without undermining innovation, access, or long-term health outcomes. PFCD's Vice President of Policy Candace DeMatteis and Global Colon Cancer Association CEO Andrew Spiegel dive into the real-world consequences of the federal government’s proposed “Most Favored Nation” (MFN) drug pricing model for cancer patients. They explore how importing foreign price controls could restrict access to cutting-edge treatments, slow innovation, and jeopardize the U.S. leadership in cancer research. In this conversation, PFCD ’s Ken Thorpe and Caregiver Action Network CEO Marvell Adams examine how “Most Favored Nation” drug pricing could reshape access to medicines for Medicaid beneficiaries. They discuss the potential ripple effects on caregivers, including added burdens from restricted access or disrupted care, and consider the broader equity implications for vulnerable populations. The discussion also explores practical policy alternatives that protect affordability while preserving innovation and reliable access to lifesaving treatments. Hear what National Organization for Rare Diseases CEO Pam Gavin has to say about the impacts of adopting "Most Favored Nation" and foreign reference pricing on people's access to lifesaving therapies for rare disease. Listen to what former Congressman Larry Bucshon, MD thinks as he sheds light on concerns about the proposal and its impact on people living with chronic conditions, particularly related to patient access, discriminatory value metrics like the QALY, and threats to future innovation. PFCD Statements and Comment Letters December 19, 2025 The Partnership to Fight Chronic Disease (PFCD) released the following statement in response to the Centers for Medicare and Medicaid Services (CMS) announcement of mandatory demonstration projects that would implement Most Favored Nation (MFN) drug pricing in Medicare Parts B and D. August 1, 2025 The Partnership to Fight Chronic Disease (PFCD) issued the following statement in response to President Trump’s most recent efforts to impose “Most Favored Nation” (MFN) drug pricing, which poses considerable risks to patient access, particularly to people living with one or more chronic diseases. May 12, 2025 The Partnership to Fight Chronic Disease (PFCD) issued the following statement in strong opposition to President Donald Trump’s "Most Favored Nation" (MFN) executive order, which aims to tie prescription drug prices in the U.S. to those in foreign countries May 5, 2025 The Partnership to Fight Chronic Disease (PFCD) today called on Congressional leaders and the Trump Administration to ensure that treatment access for people living with chronic diseases in Medicaid remains a priority across new policies that aim to make America healthy now and in the future.
- Fact Sheets - In the States | Partnership to Fight Infectious Disease
Partnership to Fight Infectious Disease is a group of patients, providers, community organizations, business and labor groups, and health policy experts working to advance awareness and action on antimicrobial resistance. Fact Sheet: Human & Economic Toll of Increase in Resistant Infections (In the States) Click on each state to download the correspondent fact sheet: OH KY WV NY PA NH CT NJ MD DE GA ME MA VT VA AZ NM AR MI OR AL CA CO ID IL IN IA KS LA MN MS MT NE NV ND OK SD TN TX UT WY AK HI WA MO WI DC RI FL NC SC
Blog Posts (62)
- New Poll of Midterm Voters Shows Overwhelming, Bipartisan Support for Passage of the ASAP Act (H.R.6130 / S.3267) This Year
With strong public support and significant momentum, Congress has an opportunity to ensure Medicare policy keeps pace with rapidly advancing Alzheimer’s science WASHINGTON, D.C. – A new poll of 2026 midterm voters reveals overwhelming, bipartisan support for passing the Alzheimer’s Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), legislation that would expand access to innovative tools for earlier Alzheimer’s detection. The findings also underscore strong public support for making Alzheimer’s disease a national priority and demonstrate that voters want Congress to act during the lame duck session. Lake Research Partners and The Tarrance Group surveyed 1,196 registered voters who cast ballots in the 2026 elections and found strong support for Alzheimer’s legislative solutions: Nearly nine in ten voters (89%) support the Alzheimer’s Screening and Prevention (ASAP) Act, with 76% strongly supporting the legislation. Support for the ASAP Act is broad across the political spectrum, with 95% of Democrats, 87% of independents, and 83% of Republicans expressing support. 70% say it is important for Congress to prioritize passing the ASAP Act during the lame-duck session, including nearly 36% who say it is very important. This urgency is shared across party lines. Majorities of Democrats (79%), independents (68%), and Republicans (62%) say passing the legislation this year should be a priority. Notably, nearly half of Democrats (44%) and independents (47%) say it is very important for Congress to act before the end of the year. More than three-quarters of voters (77%) say fighting Alzheimer’s should be a national priority. “These findings reinforce that addressing Alzheimer’s disease is not a partisan issue. Voters across the political spectrum recognize the devastating impact this disease has on millions of American families and want to see meaningful action,” said Ken Thorpe, Honorary Chair of PFCD. “Congress has already demonstrated important leadership in advancing solutions to improve Alzheimer’s detection and care. Now is the time to build on that momentum and get the ASAP Act across the finish line.” As scientific innovation continues to expand opportunities for earlier identification of Alzheimer's disease, it is critical that policies keep pace to ensure timely patient access to breakthrough tools. The ASAP Act would establish a pathway for Medicare coverage of FDA-cleared blood tests for early Alzheimer’s screening through an evidence-based process. The legislation has already garnered significant momentum on Capitol Hill and across the patient advocacy community. The ASAP Act has secured over 235 cosponsors in the House and nearly 60 cosponsors in the Senate, reflecting broad, bipartisan support in both chambers. The House Ways and Means Committee also advanced the legislation unanimously in a 40-0 vote. PFCD joined more than 525 organizations in signing a coalition letter, spearheaded by the Alzheimer’s Impact Movement (AIM) and the LEAD Coalition, urging Congress to advance the legislation. With strong bipartisan support from lawmakers, patient advocates, and the public alike, Congress has an opportunity to translate this momentum into meaningful progress for the millions of Americans impacted by Alzheimer’s disease. “Voters have spoken,” said Thorpe. “Across the political spectrum they support early detection, are eager for national action on Alzheimer's, and urge Congress to deliver. The call is bipartisan, broad, and unambiguous. The window to act is now.” Results of the poll can be found HERE. ###
- CMS Final Rule Threatens Innovation and Future Treatment Options for Patients
WASHINGTON, D.C. (November 5, 2026) The Partnership to Fight Chronic Disease (PFCD) expressed serious concern today following the Centers for Medicare & Medicaid Services' (CMS) finalization of policies affecting fixed-dose combination (FDC) therapies under the Medicare Drug Price Negotiation Program (CMS-4215-F). By potentially discouraging the development of innovative treatment combinations and more convenient ways to administer medicines, the rule risks limiting future options for millions of Americans living with serious chronic conditions. The stakes are particularly high for cancer patients. More than 600,000 Americans are diagnosed each year with lung cancer, melanoma, kidney, bladder, head and neck, or stomach cancers combined. For patients facing these diagnoses, advances in treatment can mean fewer infusions, less time traveling to medical appointments, reduced treatment burdens, and more time working, caring for family, and living their lives. Innovations that combine therapies or simplify how medicines are administered can improve the patient experience, lighten caregiver burden and potentially lead to better outcomes. "Patients living with cancer and other chronic diseases need access to more treatment options, not fewer," said PFCD Chair Kenneth E. Thorpe. "For someone undergoing cancer treatment, an innovation that reduces hours spent in an infusion center or eliminates repeated trips to the hospital can make an enormous difference. Policies that discourage these advances fail to recognize the real-world challenges patients and families face every day." The impact could extend beyond cancer. Restricting innovation in how treatments are delivered could set a precedent affecting patients with other serious chronic conditions, limiting future options that improve outcomes, reduce treatment burdens, and support quality of life for the millions of Americans living with one or more chronic illnesses. Affordability matters, but lowering drug costs should not come at the expense of innovations that improve patient outcomes and quality of life. PFCD urges CMS and Congress to address the unintended consequences of this policy and protect incentives to develop treatments that are more effective, accessible, and less burdensome for patients. ###
- Expanding Access to Untested Peptides Raises Patient Safety Concerns
WASHINGTON, D.C. (October 28, 2026) In response to today's announcement by the U.S. Department of Health and Human Services (HHS) allowing the temporary compounding of certain peptides lacking FDA approval, the Partnership to Fight Chronic Disease (PFCD) issued the following statement: “For millions of Americans managing one or more chronic conditions, access to safe, effective treatments is essential to maintaining their health and quality of life. Medical innovation offers tremendous promise, but expanding access to products without adequate evidence of their safety, quality, and effectiveness can expose patients to unnecessary and poorly understood risks. “People living with chronic conditions often face complex treatment regimens, multiple medications, and heightened vulnerability to adverse effects or drug interactions. The potential for dangerous interactions among FDA-approved prescription medicines and unregulated compounded products puts patients at significant risk. Expanding access to unproven products without sufficient clinical evidence raises serious concerns and in no way confirms that broader availability means a product has been deemed safe and effective. “PFCD urges HHS and FDA to maintain rigorous, science-based safeguards, transparent patient information, and meaningful oversight. Americans deserve access to promising innovations, but not if it compromises the confidence that the treatments they receive have been appropriately evaluated and will not put their health at greater risk. Expanding access should never come at the expense of patient safety or public confidence in the treatments on which Americans rely.” ###
